title: Treatment of hepatic metastases from gastric or gastroesophageal adenocarcinoma with computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT).
abstract: BACKGROUND
  This retrospective analysis was performed to evaluate the clinical outcome of patients with hepatic metastases from gastric or gastroesophageal adenocarcinoma who were treated with computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT).
  
  
  METHODS
  Eight patients with a total number of 12 isolated hepatic metastases from histologically-proven adenocarcinoma of the lower oesophagus or stomach, were treated with CT-HDRBT. Gadoxetic acid-enhanced magnetic resonance imaging (MRI) was performed 6 and 12 weeks after CT-HDRBT and then every 3 months to evaluate treatment efficacy.
  
  
  RESULTS
  The median follow-up time was 6.1±6.8 months. Lesion size ranged from 14 to 68 mm in diameter with a median of 46±21 mm. No patient developed a local recurrence. Five patients developed systemic progression after a median time of 3.7±3.6 months (three in the liver, one in liver and bone and one in liver and resection margin from gastrectomy). One patient died 3.4 months after CT-HDRBR because of liver progression with cholestasis. No major complications associated with the treatment occurred.
  
  
  CONCLUSIONS
  CT-HDRBT might be a feasible alternative to surgical resection of liver metastases from gastric or gastroesophageal adenocarcinoma in selected patients and seems to have similar outcome rates as surgical resection in our small collective.
authors.affiliation: Department of Diagnostic and Interventional Radiology, Charité Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. dominik.geisel@charite.de
authors.forename: Dominik
authors.initials: D
authors.lastname: Geisel
authors.forename: Timm
authors.initials: T
authors.lastname: Denecke
authors.forename: Federico
authors.initials: F
authors.lastname: Collettini
authors.forename: Christian
authors.initials: C
authors.lastname: Grieser
authors.forename: Peter
authors.initials: P
authors.lastname: Wust
authors.forename: Peter
authors.initials: P
authors.lastname: Thuss-Patience
authors.forename: Bernd
authors.initials: B
authors.lastname: Hamm
authors.forename: Bernhard
authors.initials: B
authors.lastname: Gebauer
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary*; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D004938:Esophageal Neoplasms / Q000473:pathology* / Q000532:radiotherapy; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D008875:Middle Aged; D015641:Radiography, Interventional / Q000009:adverse effects / Q000379:methods; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000473:pathology* / Q000532:radiotherapy; D014057:Tomography, X-Ray Computed / Q000009:adverse effects / Q000379:methods; D016896:Treatment Outcome